Otenaproxesul is a analgesic and anti-inflammatory drug being developed by Antibe Therapeutics.

An NSAID structurally derived from naproxen, in 2016 it received approval to commence phase II clinical trials as a treatment for osteoarthritis after completing phase I clinical trials in 2015.

Other in vivo studies have demonstrated a reduction in zymosan-induced pain and inflammation and cytokine-induced bone loss.

[4] Preclinical studies have also investigated the treatment of melanoma, intestinal cancer,[5] and periodontitis.

[6] Like other NSAIDs, otenaproxesul acts as an inhibitor of the cycloxygenase (COX) enzymes, suppressing the production of prostaglandins.